Perrigo (PRGO) Accumulated Expenses (2013 - 2026)
Perrigo's (PRGO) quarterly Accumulated Expenses came in at $153.5 million in Q1 2026, down 39.52% year-on-year from $253.8 million in Q1 2025, and up 36.81% on a QoQ basis from $112.2 million in Q4 2025.
Perrigo (PRGO) Accumulated Expenses (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Accumulated Expenses data on file, last reported at $153.5 million in Q1 2026.
- On a quarterly basis, Accumulated Expenses fell 39.52% year-over-year to $153.5 million in Q1 2026; TTM through Mar 2026 was $153.5 million, a 39.52% decrease from a year earlier, with the FY2025 full-year figure at $112.2 million, down 8.93% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $153.5 million, up from $112.2 million in the prior quarter.
- Over the last five years, Accumulated Expenses for PRGO reached as high as $363.1 million in Q3 2025 and fell as low as $88.6 million in Q2 2022.
- Historically, Accumulated Expenses has averaged $177.2 million across 5 years, with a median of $127.0 million in 2023.
- Across the five-year window, Accumulated Expenses sank 55.8% in 2022 and jumped 237.09% in 2024, its largest moves.
- Year by year, Accumulated Expenses stood at $136.4 million in 2022, then fell by 6.89% to $127.0 million in 2023, then dropped by 2.99% to $123.2 million in 2024, then decreased by 8.93% to $112.2 million in 2025, then surged by 36.81% to $153.5 million in 2026.
- Per Business Quant data, the three most recent Accumulated Expenses figures were $153.5 million in Q1 2026, $112.2 million in Q4 2025, and $363.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 153.50 Mn |
| Dec 31, 2025 | 112.20 Mn |
| Sep 27, 2025 | 363.10 Mn |
| Jun 28, 2025 | 122.40 Mn |
| Mar 29, 2025 | 253.80 Mn |
| Dec 31, 2024 | 123.20 Mn |
| Sep 28, 2024 | 227.00 Mn |
| Jun 29, 2024 | 125.40 Mn |
| Mar 30, 2024 | 359.00 Mn |
| Dec 31, 2023 | 127.00 Mn |
| Sep 30, 2023 | 262.30 Mn |
| Jul 1, 2023 | 104.40 Mn |
| Apr 1, 2023 | 106.50 Mn |
| Dec 31, 2022 | 136.40 Mn |
| Oct 1, 2022 | 242.70 Mn |
| Jul 2, 2022 | 104.10 Mn |
| Apr 2, 2022 | 88.60 Mn |
| Dec 31, 2021 | 118.50 Mn |
| Oct 2, 2021 | 339.90 Mn |
| Jul 3, 2021 | 235.50 Mn |